Home/Pipeline/TEM-1657 (Oral)

TEM-1657 (Oral)

Psoriasis

Pre-clinicalActive

Key Facts

Indication

Psoriasis

Phase

Pre-clinical

Status

Active

Company

Temisis

About Temisis

Temisis Therapeutics is a Paris-based, private biotech advancing novel small molecules for inflammatory diseases, with a primary focus on psoriasis. Its lead asset, TEM-1657, has shown in preclinical models to achieve rapid symptom remission and complete healing without the side effects, such as skin thinning, associated with current corticosteroids or oral therapies like apremilast. The company is positioned to address a significant unmet need in a large global market, though it remains at a preclinical stage with no disclosed clinical data, partnerships, or financing details.

View full company profile

Therapeutic Areas

Inflammatory Diseases Dermatology Autoimmune Diseases

Other Psoriasis Drugs

Drug	Company	Phase	Status
Autoimmune psoriasis candidate	Nyrada	Preclinical	Active
CYPS317	FibroBiologics	Discovery	Active
PEP Biologic™	Intent Biologics	Unknown	Active
DMT410	Dermata Therapeutics	Preclinical	Exploratory
IL23R program	Acellera	Pre-clinical	Hit-to-Lead
Undisclosed Psoriasis Program	Nepsone	Preclinical	Active
TEM-1657 (Topical)	Temisis	Pre-clinical	Active
AIM Platform	Phaim Pharma	Pre-clinical	Active
orismilast	UNION therapeutics	Phase 2	Active
Laikangqita Monoclonal Antibody	Livzon Pharmaceutical	NDA	Marketing application accepted and granted priority review
CT-P55	Celltrion	Phase 3	Active
JNJ-77242113	Johnson & Johnson	Phase 3	Active